Product Overview
Tesamorelin 5 mg by British Dragon is supplied as a vial labeled with 5 mg of Tesamorelin. Tesamorelin is a synthetic growth hormone-releasing factor (GHRF/GHRH) analogue that stimulates endogenous growth hormone secretion and downstream IGF-1 signaling. Pharmaceutical Tesamorelin has an established medical application, but an independently supplied 5 mg vial should not automatically be considered equivalent to an approved formulation.
Product Class
Tesamorelin belongs to the growth hormone-releasing hormone analogue class. Unlike recombinant HGH, it does not directly supply growth hormone; instead, it stimulates the pituitary through GHRH receptors. It is not an anabolic steroid, SARM or androgen.
Indications
Approved Tesamorelin is indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved as a general weight-loss medicine. Outside this indication, Tesamorelin is discussed in metabolic, body-composition and GH-axis research, but these applications should be distinguished from established clinical use.
Mechanism of Action
Tesamorelin activates pituitary GHRH receptors, increasing endogenous pulsatile growth hormone secretion. Increased GH subsequently stimulates hepatic and peripheral production of IGF-1. The resulting GH/IGF-1 signaling influences visceral adipose tissue, protein metabolism and tissue remodeling.
Potential Benefits
Clinical research in adults with HIV-associated lipodystrophy has demonstrated meaningful reductions in visceral abdominal adipose tissue. Tesamorelin can also increase circulating IGF-1. Its established effect is specifically reduction of excess visceral abdominal fat in the indicated population rather than generalized weight-loss treatment.
Synergy & Stacking
Ipamorelin stimulates GH through the ghrelin/GHS-R1a receptor, whereas Tesamorelin acts through the GHRH receptor. These complementary mechanisms explain why GHRH analogues and GHRPs are sometimes discussed together, although this does not establish an approved combination protocol.
HGH supplies growth hormone directly and therefore acts further downstream. Combining Tesamorelin with HGH, CJC-1295, Sermorelin, IGF-1 analogues or other GH-axis compounds can increase overlapping endocrine effects and is not part of standard approved Tesamorelin therapy.
HRT/TRT Application
Tesamorelin has no direct role in testosterone replacement therapy. It neither supplies Testosterone nor activates androgen receptors. It influences the GH/IGF-1 axis and should not be considered a substitute for either TRT or medically indicated recombinant HGH replacement.
Dosing and Use
The British Dragon product is labeled as containing 5 mg per vial. Approved Tesamorelin formulations have product-specific strengths, reconstitution instructions and dosing requirements and are not necessarily interchangeable. Therefore, the 5 mg vial designation represents stated product content rather than a recommended single administration or treatment schedule.
Female Use
Tesamorelin is non-androgenic and does not produce anabolic-steroid-type virilization. Its approved indication can apply to appropriate adult patients regardless of sex. Pregnancy is a contraindication for approved Tesamorelin therapy because reducing visceral adipose tissue during pregnancy offers no benefit and may pose fetal risk.
Comparative Analysis
Tesamorelin vs Ipamorelin: Tesamorelin activates GHRH receptors, while Ipamorelin activates GHS-R1a/ghrelin receptors to stimulate GH release.
Tesamorelin vs Sermorelin: Both are GHRH analogues. Tesamorelin has an established pharmaceutical indication for excess abdominal fat in HIV-associated lipodystrophy, while Sermorelin's historical pharmaceutical use centered on GH-related diagnostic and pediatric applications.
Tesamorelin vs CJC-1295: Both target GHRH signaling, but they differ structurally and pharmacologically; CJC-1295 remains primarily investigational.
Tesamorelin vs HGH: Tesamorelin stimulates endogenous GH release, whereas Somatropin directly supplies recombinant human growth hormone.
Tesamorelin vs Semaglutide: Tesamorelin works through the GH/IGF-1 axis and is approved for a specific visceral-fat indication. Semaglutide activates GLP-1 receptors and is used in approved products for diabetes and weight-management indications.
Conclusion
Tesamorelin 5 mg by British Dragon is a GHRH analogue supplied as a 5 mg vial. Tesamorelin stimulates endogenous GH and IGF-1 signaling and has an established pharmaceutical role in reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Its mechanism distinguishes it from direct HGH, GHRPs such as Ipamorelin and metabolic agents such as Semaglutide. The 5 mg vial strength itself should not be interpreted as an established dose or as equivalent to an approved Tesamorelin formulation.
Tesamorelin 5 mg FAQ
What is Tesamorelin?
Tesamorelin is a synthetic GHRH/GHRF analogue that stimulates endogenous growth hormone secretion and increases downstream IGF-1 signaling.
Is Tesamorelin FDA approved?
Yes, specific pharmaceutical Tesamorelin formulations are FDA approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. This does not automatically confer approved status on independently manufactured Tesamorelin products.
Is Tesamorelin a weight-loss drug?
No. Approved labeling specifically states that Tesamorelin is not indicated for general weight-loss management.
Does Tesamorelin increase IGF-1?
Yes. Stimulation of endogenous GH increases downstream IGF-1, which is why IGF-1 monitoring is relevant during approved therapy.
